Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Xu L, Shadman M, Flinn IW, Levy MY, Porter R, Burke JM, Zafar SF, Cultrera JL, Misleh J, Kingsley EC, Yimer HA, Freeman B, Chaudhry A, Tumula PK, Gandhi MD, Crescenzo R, By K, Cohen A, Chen DY, Idoine A, Manda S, Sharman JP, Ramakrishnan V.
Xu L, et al. Among authors: by k.
Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.283861. Online ahead of print.
Haematologica. 2024.
PMID: 38268449
Free article.